These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38700461)

  • 1. Use of medical therapy and risk of clinical events according to frailty in heart failure patients - A real-life cohort study.
    Zahir Anjum D; Strange JE; Fosbøl E; Garred CH; Elmegaard M; Andersson C; Jhund PS; McMurray JJV; Petrie MC; Kober L; Schou M
    Eur J Heart Fail; 2024 Aug; 26(8):1717-1726. PubMed ID: 38700461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction.
    Butler J; Yang M; Manzi MA; Hess GP; Patel MJ; Rhodes T; Givertz MM
    J Am Coll Cardiol; 2019 Mar; 73(8):935-944. PubMed ID: 30819362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.
    Vicent L; Cinca J; Vazquez-García R; Gonzalez-Juanatey JR; Rivera M; Segovia J; Pascual-Figal D; Bover R; Worner F; Delgado-Jiménez J; Fernández-Avilés F; Martínez-Sellés M
    Intern Med J; 2019 Dec; 49(12):1505-1513. PubMed ID: 30887642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
    Ehteshami-Afshar S; Mooney L; Dewan P; Desai AS; Lang NN; Lefkowitz MP; Petrie MC; Rizkala AR; Rouleau JL; Solomon SD; Swedberg K; Shi VC; Zile MR; Packer M; McMurray JJV; Jhund PS; Hawkins NM
    J Am Heart Assoc; 2021 Feb; 10(4):e019238. PubMed ID: 33522249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
    JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
    Albert NM; Swindle JP; Buysman EK; Chang C
    J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.
    Vaduganathan M; Fonarow GC; Greene SJ; DeVore AD; Kavati A; Sikirica S; Albert NM; Duffy CI; Hill CL; Patterson JH; Spertus JA; Thomas LE; Williams FB; Hernandez AF; Butler J
    JACC Heart Fail; 2020 Jun; 8(6):469-480. PubMed ID: 32387066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
    Vaduganathan M; Claggett BL; Jhund PS; Cunningham JW; Pedro Ferreira J; Zannad F; Packer M; Fonarow GC; McMurray JJV; Solomon SD
    Lancet; 2020 Jul; 396(10244):121-128. PubMed ID: 32446323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-Based Process Performance Measures and Clinical Outcomes in Patients With Incident Heart Failure With Reduced Ejection Fraction: A Danish Nationwide Cohort Study.
    Schjødt I; Johnsen SP; Strömberg A; DeVore AD; Valentin JB; Løgstrup BB
    Circ Cardiovasc Qual Outcomes; 2022 Apr; 15(4):e007973. PubMed ID: 35272503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of frailty based on a comprehensive frailty assessment in patients with heart failure.
    Hamada T; Kubo T; Kawai K; Nakaoka Y; Yabe T; Furuno T; Yamada E; Kitaoka H;
    ESC Heart Fail; 2024 Aug; 11(4):2076-2085. PubMed ID: 38549188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Optimal Plasma Volume Status in Heart Failure in Relation to Clinical Outcome.
    Martens P; Nijst P; Dupont M; Mullens W
    J Card Fail; 2019 Apr; 25(4):240-248. PubMed ID: 30528705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial.
    Pandey A; Segar MW; Singh S; Reeves GR; O'Connor C; Piña I; Whellan D; Kraus WE; Mentz RJ; Kitzman DW
    Circulation; 2022 Jul; 146(2):80-90. PubMed ID: 35616018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure.
    Greene SJ; Ayodele I; Pierce JB; Khan MS; Lewsey SC; Yancy CW; Alhanti B; Van Spall HGC; Allen LA; Fonarow GC
    JACC Heart Fail; 2024 Aug; 12(8):1365-1377. PubMed ID: 38597866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial.
    Fiuzat M; Ezekowitz J; Alemayehu W; Westerhout CM; Sbolli M; Cani D; Whellan DJ; Ahmad T; Adams K; Piña IL; Patel CB; Anstrom KJ; Cooper LS; Mark D; Leifer ES; Felker GM; Januzzi JL; O'Connor CM
    JAMA Cardiol; 2020 Jul; 5(7):757-764. PubMed ID: 32319999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physical Frailty and Use of Guideline-Recommended Drugs in Patients With Heart Failure and Reduced Ejection Fraction.
    Kondo T; Adachi T; Kobayashi K; Okumura T; Izawa H; Murohara T; McMurray JJV; Yamada S
    J Am Heart Assoc; 2023 Jun; 12(12):e026844. PubMed ID: 37301739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frailty Assessment in Advanced Heart Failure.
    Madan SA; Fida N; Barman P; Sims D; Shin J; Verghese J; Piña I; Jorde U; Patel SR
    J Card Fail; 2016 Oct; 22(10):840-4. PubMed ID: 26883168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry.
    Komajda M; Cowie MR; Tavazzi L; Ponikowski P; Anker SD; Filippatos GS;
    Eur J Heart Fail; 2017 Nov; 19(11):1414-1423. PubMed ID: 28463464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
    Balmforth C; Simpson J; Shen L; Jhund PS; Lefkowitz M; Rizkala AR; Rouleau JL; Shi V; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    JACC Heart Fail; 2019 Jun; 7(6):457-465. PubMed ID: 31078482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.